MERZ-AESTHETICS
1.2.2024 09:01:30 CET | Business Wire | Press release
Merz Aesthetics is presenting at the 2024 International Master Course on Aging Science (IMCAS) World Congress a total of 5 abstracts highlighting the field of regenerative aesthetics and how its product portfolio is contributing. This year’s IMCAS is the 25th edition of the largest scientific aesthetics congress worldwide beginning Thursday, February 1st to Saturday, February 3.
“Merz Aesthetics is looking forward to sharing these new findings, as they provide strong scientific evidence to support the evolving field of regenerative aesthetics,” said Terri Phillips, M.D., Chief Medical Affairs Officer, Merz Aesthetics. “We take pride in the innovation of our product portfolio and how it’s helping to shape the future of the aesthetics industry.”
“Our focus in this year’s Merz Aesthetics sponsored symposium at the IMCAS Congress is the future of regenerative biostimulation with Radiesse”, said Gonzalo Mibelli, President EMEA, Merz Aesthetics. “Together with a panel of renowned industry experts we discuss the topic of skin regeneration, share insights into techniques and personalized treatment approaches aligned with our Merz Aesthetics commitment on scientific exchange and innovation.”
Merz Aesthetics organized a program led by notable medical aesthetic experts, participating in various IMCAS sessions and presenting new data throughout the event.
- Merz Aesthetics sponsored symposium “Mastering regenerative biostimulation” – Dr. Gabriela Casabona, Dr. Tatjana Pavicic, Dr. Jani van Loghem, Dr. Bianca Viscomi, Friday, February 2, 2024, 4:00 p.m. – 6:00 p.m. CEST
- Merz Aesthetics support of IMCAS Cadaver Workshop – Anatomist Dr. Nicholas Moellhoff and Aesthetic Specialist Dr. Jonathan Kadouch, Thursday, February 1, 2024, 2:30 p.m. – 3:30 p.m. CEST
- IMCAS Product Analysis Session “Biostimulators” – Dr. Alec McCarthy, Director Regenerative Aesthetics, Merz Aesthetics, Friday, February 2, 2024, 8:30 a.m. ‒ 10:00 a.m. CEST
- IMCAS Product Analysis Session “Toxins” – PH.D. Andy Curry, associate medical director, Merz Aesthetics, Saturday, February 3, 2024, 8:30 a.m. ‒ 10:00 a.m. CEST
- IMCAS Economic Tribune Roundtable – Bob Rhatigan, CEO Merz Aesthetics, Friday, February 2, 2024, 2:00 p.m. – 3:30 p.m. CEST
Booth Talks
- Treatment Options for Hand Rejuvenation - Dr. Elena Bagnenko, Thursday, February 1, 2024, 1:00p.m. – 1.30 p.m.
- Innovative Technique for Tear Trough Correction - Dr. Yahia Hashish, Thursday, February 1, 2024, 3:30p.m. – 4.00 p.m.
- What are THE Really Important Aspects when using CaHA as a Regenerative Biostimulator? - Dr. Gabriela Casabona, Friday, February 2, 10:00 a.m. – 10.30 a.m.
- Advancing Skin Radiance, Dr. Juan Martín Zárate González, Friday, February 2, 1:00 p.m. – 1.30 p.m.
- Combination of Treatments for Improving Skin Quality - Dr. Ana Diez Gandia, Saturday, February 3, 2024, 10:00 a.m. – 10.30 a.m.
E-Poster Presentations
Virtual posters will be available for viewing on-site throughout the congress and displayed on the virtual e-poster platform with detailed abstracts.
- A review of Radiesse as a regenerative aesthetic treatment. Presenting author: Dr. Shino Bay Aguilera. Co-Authors: Dr. Alec McCarthy, Dr. Saami Khalifian, Dr.Z. Paul Lorenc, Dr. Katherine Goldie, Dr. W. Gregory Chernoff
- The evolving field of regenerative aesthetics. Presenting author: Dr. Katherine Goldie
- Physical properties of diluted Radiesse. Presenting author: Dr. Vasanop Vachiramon. Co-authors: Dr. Chayanee Likitwattananurak, Dr. Nawara Sakpuwadol, Dr. Tanat Yongpisarn
- Attraction of fibroblasts by Micro-Focused Ultrasound (MFU-V). Presenting author: Dr. Kay Marquardt. Co-authors: Dr. F. Wegener, Dr. Nils Warfving, Dr. Christian Hartmann, Dr. Dr. Thomas Hengl
- Retrospective case series following patients treated with a combination of CPM-HA and CaHA fillers. Presenting author: Dr. Bianca Viscomi Co-authors: Dr. Yana Yutskovskaya, Dr. Heidi Waldorf, Dr. Ting Song Lim
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2024 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201288217/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 20266.5.2026 12:30:00 CEST | Press release
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2026, and provide an update on recent developments, on May 13, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 13, 2026. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/144892287. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new p
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)6.5.2026 12:25:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirteen newly hired non-executive employees. The equity awards were granted on May 1, 2026 and consisted of options to purchase an aggregate of 125,335 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 59,625 shares. The options have an exercise price per share equal to $9.01, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Aircall Acquires Vogent to Advance Its AI Voice Agent Built Natively into Business Phones6.5.2026 12:03:00 CEST | Press release
Aircall, the AI-powered customer communications platform trusted by more than 22,000 businesses worldwide, today announced the acquisition of Vogent, an AI voice agent company. The acquisition adds a new layer of specialized voice AI technology to Aircall’s platform – strengthening the technology behind Aircall’s AI Voice Agent and moving it from already great to best-in-class. While AI agents' chat or email based communication channels have exploded in popularity, voice is its own discipline – with unique demands around timing, interruption handling, call flows, and production reliability. Voice channel also comes with the highest expectations from customers, further putting scrutiny around the readiness of the technology. For many businesses deploying AI voice agents, the experience has not lived up to the hype. With Vogent, Aircall enhances its AI Voice Agents with a deeper set of specialized AI technologies, including advanced speech models, more reliable turn-taking, and higher pr
AB InBev Wins Cannes Lions Creative Marketer of the Year for an Unprecedented Third Time6.5.2026 12:03:00 CEST | Press release
The world’s leading brewer’s approach to creativity as a competitive advantage results in strong performance and increased revenues The Cannes Lions International Festival of Creativity has announced AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD) as the 2026 Creative Marketer of the Year. The honorary accolade is presented to a marketer that has amassed a body of iconic, Lion-winning work over a sustained period of time. AB InBev’s continued commitment to using creativity as a growth lever across its portfolio resulted in it winning an impressive 37 Lions at last year’s Festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506536538/en/ AB InBev is the first company in Cannes Lions’ history to be honoured with the award for a third time. Since 2021 the global brewer has embarked on a journey of inorganic to organic growth, betting on creativity as a key competitive advantage that has contributed to strong perfor
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates6.5.2026 12:00:00 CEST | Press release
Total global revenues of $1.5 billion for the first quarter, an increase of 35% from the prior year Foundational BRUKINSA (zanubrutinib) global revenues of $1.1 billion for the first quarter, an increase of 38% from the prior year Diluted GAAP Earnings per American Depository Share (ADS) of $1.96 for the first quarter; non-GAAP diluted Earnings per ADS of $3.24 for the first quarter BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the first quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “These strong first-quarter results reinforce BeOne’s continued growth as a global oncology leader, driven by disciplined commercial execution, and underpinned by our established hematology leadership, and an impressive, rapidly emerging solid tumor pipeline. The sustained competitive advantages of our global superhighway for clinical development and manufacturing are now cle
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom